What have pharmacies paid for Cyclophosphamide since 2013?
What pharmacies pay, not what you pay. Cyclophosphamide has 5 products in the CMS NADAC survey, 3 products with year-end prices in more than one year. NADAC is what pharmacies pay to acquire a drug, not what a patient is charged. Cyclophosphamide 50 MG Capsule: $9.34 per unit at the 2014 survey and $1.79 at 2026 (−81%, thin).
Not medical or financial advice. This page reports what pharmacies pay to acquire a drug, from the CMS NADAC survey. It is not what you will be charged, and it says nothing about which medicine is right for you. Ask your pharmacist or prescriber.
Cyclophosphamide5 products in NADAC
3products with a price history
Cyclophosphamide has 5 products in the CMS NADAC survey, 3 products with year-end prices in more than one year. NADAC is what pharmacies pay to acquire a drug, not what a patient is charged.
Between each product's first and latest year-end survey, 1 product costs pharmacies less and none costs more, by more than 5 percent, per unit as CMS states it.
2 of the changes rest on fewer than 3 priced NDCs at one end and are marked thin: a median over one or two NDCs reflects which NDCs were priced as much as a price movement.
This is a per-unit acquisition cost, not a retail price, a copay or an insurer's price, and it says nothing about why a price moved.
Cyclophosphamide 50 MG Capsule
Generic
$9.34 per unit at the 2014 year-end survey (1 NDC) and $1.79 at the 2026 survey (4 NDCs): −81%, a thin comparison.
year-end median across the NDCs pricedlowest to highest NDC
Year-end survey
Median per unit
Lowest to highest
NDCs priced
2014 (2014-12-31)
$9.34
1
2015 (2015-12-30)
$8.76
1
2016 (2016-12-28)
$9.40
1
2017 (2017-12-27)
$9.58
1
2019 (2019-12-25)
$11.11
4
2020 (2020-12-30)
$8.05
5
2023 (2023-12-27)
$4.07
4
2024 (2024-12-25)
$2.73
4
2025 (2025-12-31)
$1.76
3
2026 (2026-11-11)
$1.79
4
Cyclophosphamide 25 MG Capsule
Generic
$2.41 per unit at the 2024 year-end survey (4 NDCs) and $1.15 at the 2026 survey (4 NDCs): −52%.
year-end median across the NDCs pricedlowest to highest NDC
Year-end survey
Median per unit
Lowest to highest
NDCs priced
2024 (2024-12-25)
$2.41
4
2025 (2025-12-31)
$1.17
3
2026 (2026-11-11)
$1.15
4
Cyclophosphamide 50 MG Tablet
Generic
$2.36 per unit at the 2013 year-end survey (1 NDC) and $2.80 at the 2014 survey (1 NDC): +19%, a thin comparison.
year-end median across the NDCs pricedlowest to highest NDC
Year-end survey
Median per unit
Lowest to highest
NDCs priced
2013 (2013-12-25)
$2.36
1
2014 (2014-12-31)
$2.80
1
Cyclophosphamide 25 MG Tab
Generic
Priced once, at the 2013 year-end survey: $1.32 per unit across 1 NDC.
Year-end survey
Median per unit
Lowest to highest
NDCs priced
2013 (2013-12-25)
$1.32
1
Cyclophosphamide 500 MG Vial
Generic
Priced once, at the 2013 year-end survey: $228 per unit across 2 NDCs.
Year-end survey
Median per unit
Lowest to highest
NDCs priced
2013 (2013-12-25)
$228
2
CMS National Average Drug Acquisition Cost, year-end surveys 2013 to 2026. A pharmacy acquisition cost, not a retail price. About NADAC.
Where does Cyclophosphamide sit on the generic price cliff?
Cyclophosphamide 50 MG Capsule: the first generic approval in its Orange Book group is dated 2018. Its year-end acquisition cost in 2026 is 16% of its first observed year-end price (2019). The median matched product, 8 years after its first generic approval, is at 32% (the middle half runs from 8% to 65%), so this product is inside that middle half.
median of 200 matched productsmiddle halfeach productCyclophosphamide 50 MG Capsule
This is a pattern in matched products. It does not say the first generic caused the fall, and it does not say this product's price will follow the median. See it with other drugs.
How many companies make Cyclophosphamide?
The FDA Orange Book lists 9 generic makers as marketed in its largest dosage form for Cyclophosphamide, and the first generic approval is dated 16 February 1982. The acquisition costs above are what pharmacies pay across the NDCs priced; the Orange Book count is a separate record and this page does not say that more makers lowered a price. See each maker and the patents still listed on OmniRx.